Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2018 10:24 ET | Source: LIDDS AB

Kommuniké från årsstämman i LIDDS

Den 16 maj 2018 hölls årsstämma i LIDDS AB (publ). Nedan följer sammanfattning av de beslut som fattades. Beslut fattades med erforderlig majoritet. Vid stämman var 2 418 048 (11,1 %) av totalt...
May 16, 2018 08:40 ET | Source: LIDDS AB

LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company

UPPSALA, SWEDEN - LIDDS AB (publ) has signed a license agreement for Liproca® Depot with Jiangsu Ambition Medical, a Chinese pharmaceutical company specializing in global collaborations and...
May 16, 2018 02:30 ET | Source: LIDDS AB

LIDDS: Delårsrapport januari-mars 2018

FÖRSTA KVARTALET: JANUARI - MARS 2018 Nettoomsättningen uppgick till 0,0 (0,0) KSEK Kostnaderna uppgick till 2,0 (1,8) MSEK Resultatet före och efter skatt uppgick till -2,0 (-1,8) MSEK ...
May 15, 2018 02:30 ET | Source: LIDDS AB

LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery

UPPSALA, SWEDEN - LIDDS AB (publ) is today unveiling new animal data which demonstrates that subcutaneously injected NanoZolid® can act as a depot for systemic delivery of pharmaceutically active...
April 25, 2018 14:33 ET | Source: LIDDS AB

LIDDS: Presenterar Årsredovisning 2017

För mer information, vänligen kontakta: Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.comBengt Norvik, CFO, +46 (0)730 74 68 00, bengt.norvik@liddspharma.com LIDDS utvecklar...
April 17, 2018 02:30 ET | Source: LIDDS AB

LIDDS: Kallelse till årsstämma i LIDDS AB (publ)

Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma på Virdings allé 32B i Uppsala onsdagen den 16 maj 2018 kl. 15:00. Rätt att delta och anmälan Rätt att delta i...
March 15, 2018 03:30 ET | Source: LIDDS AB

LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field

Single intratumoral injections of a NanoZolid formulated STING agonist has been proven to achieve significant effects on tumor growth reduction and overall survival. These positive effects of the...
February 22, 2018 02:30 ET | Source: LIDDS AB

LIDDS presenterar bokslutskommuniké 2017

BOKSLUTSKOMMUNIKÉ 2017 FJÄRDE KVARTALET - OKTOBER - DECEMBER 2017 Nettoomsättningen uppgick till 0,4 (0,0) KSEK Kostnaderna uppgick till 2,5 (2,1) MSEK Resultatet före och efter skatt...
February 08, 2018 02:30 ET | Source: LIDDS AB

LIDDS: Liproca® Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine

The scientific results from intratumoral injections with Liproca® Depot as confirmed by Magnetic Resonance Imaging and Spectroscopy, have been accepted for presentation at the International Society...
January 15, 2018 09:20 ET | Source: LIDDS AB

LIDDS: Nyenburgh Holding invests 13,5 MSEK in a direct share issue

LIDDS AB (publ) board has decided on a direct share issue to Nyenburgh Holding, a Dutch Life Science Fund that invests in selected European biotech- and pharma companies. The raised capital will...